http://affinitysetters.com/pedigree-boys.htm
Novavax, which began working on a vaccinde for the N1H1 virus earlier this says it produced the first batchb of the vaccinein May. Novavadx uses a technology that greatly speed the time it takes tomake vaccines. It says it has now completesd the genetic engineering and manufacture of the stockm needed to mass producethe virus. As a Novavax and the National Institutesof Health’a National Institute of Allergy and Infectious Diseases have signedr an agreement that will let government scientists evaluat e the vaccine.
“The company has committed necessarhy resources to respond as rapidly as possible to constructt and manufacture VLP vaccine against this new N1H1influenz virus,” said Novavax CEO Rahul Singhv in a statement. Novavax has the capacitu to produce large amounts the vaccine at its manufacturing facilitie sin Rockville. Novavax stock (NASDAQ: NVAX) was up 88 cent s to $2.75 per share in afternoon Its stock was trading as low as 52 cents per sharr inearly April.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment